|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No specific TPIT immunostaining was detectable in all prolactin (PRL)-, GH-, or gonadotropin-secreting adenomas.
|
12843142 |
2003 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Ptx1 was detected in 10/14 (71.4%) of growth hormone (GH)-secreting adenomas, 12/12 (100%) of prolactin (PRL)-secreting adenomas, 18/20 (90%) of adrenocorticotropic hormone (ACTH)-secreting adenomas, 6/7 (85.7%) of thyroid-stimulating hormone (TSH)-secreting adenomas, and 17/20 (85%) of clinically non-functioning adenomas, including 9/10 (90%) of gonadotropin-subunit-positive adenomas.
|
11048804 |
2000 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A functional pituitary adenoma can produce multiple anterior-pituitary hormones, such as growth hormone (GH) -producing adenomas (GHoma) with prolactin or thyrotropin stimulating hormone production in the same lineage.
|
28865461 |
2017 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Four tumors were shown to have a hypotriploid chromosomal constitution, two of which also presented structural clonal rearrangements: an isochromosome 1q,i(1)(q10) and a der(1)t(1;3)(p22;q21) were observed in two PRL-secreting adenomas, one of which also had a telomeric association involving the short arms of chromosomes 14 and 19.
|
9332478 |
1997 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Dysregulation of the signaling pathways that govern lactotrope biology contributes to tumorigenesis of prolactin (PRL)-secreting adenomas, or prolactinomas, leading to a state of pathological hyperprolactinemia.
|
25472533 |
2015 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A comparative RT-PCR approach revealed signals for both V3 receptor and CHR receptor mRNAs in 17 of 18 ACTH-secreting pituitary adenomas, and 6 of 6 normal pituitaries; in six growth hormone- or prolactin-secreting adenomas, a very faint V3 receptor signal was observed in three cases, and CRH receptor signal was undetected in all.
|
8636444 |
1996 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In 35% of the cases the adenoma was nonfunctional, while in the others it was associated with PRL, GH and/or ACTH endocrine hypersecretion syndrome.
|
12011941 |
2002 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Because human epidermal growth factor receptor 2 (HER2)/ErbB2 is overexpressed in prolactinomas and ErbB receptor ligands regulate prolactin (PRL) gene expression, we tested the role of HER2/ErbB2 in prolactinoma hormone regulation and adenoma cell proliferation to assess the rationale for targeting this receptor for prolactinoma therapy.
|
21106881 |
2011 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition,1 of 2 ACTH tumors but no GH (n = 4) or PRL (n = 1) adenoma examined were hypermethylated.
|
11740049 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Pit-1 mRNA was detected in 12 (80%) of 15 prolactin-producing adenomas.
|
8733768 |
1996 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Forty-four GH-secreting adenomas, 7 prolactin (PRL)-secreting adenomas and 32 clinically non-functioning adenomas were examined for the presence of point mutations in codon 201 and 227 of the Gs alpha gene using a nested PCR and direct sequencing of DNA extracted from fresh tissue or paraffin-embedded pituitary adenoma samples.
|
11182759 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
These adenomas included 13 clinically non-functioning adenomas, 1 GH/PRL-producing adenoma, 6 GH-producing adenomas, 2 PRL-producing adenomas and 1 ACTH-producing adenoma.
|
8881451 |
1996 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
|
27708194 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The purpose of this report is to describe the morphologic changes seen in PRL-producing adenomas after short-term dopamine agonist treatment.
|
16328513 |
2006 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Bromocriptine (BC) is a well known anti-neoplasic agent in human PRL secreting adenomas although its effect on PRL cells is far from clear.
|
11680511 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Histotype of atypical adenomas figured out to be nonfunctioning in 23 cases (46 %), PRL secreting in 10 cases (20 %), ACTH secreting and GH secreting each apart in 8 patients (16 %), and in a single case a GH/PRL secreting adenoma (2 %).
|
27215912 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) molecule, BIM-23A387 and of new somatostatin-dopamine chimeric molecules with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.
|
15994755 |
2005 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
AIP mutation-positive patients have a characteristic clinical phenotype with usually young- or childhood-onset growth hormone (GH) and/or prolactin (PRL)-secreting adenomas and can be seen in cases with no apparent family history as well.
|
23652674 |
2013 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Both are negatively coupled to adenylyl cyclase and inhibit prolactin secretion, but, in addition, the shortest one (D2S) is more efficiently coupled to phospholipase C. Consequently, we also investigated whether expression of a particular D2 receptor isoform was preferentially affected in resistant adenomas.
|
7969790 |
1994 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We also immunostained urocortin in 52 cases of human anterior pituitary adenomas, including GH-producing adenomas (n = 14), ACTH-producing adenomas (n = 13), PRL-producing adenomas (n = 11), and nonfunctioning hormonally inactive adenomas (n = 14).
|
9360550 |
1997 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Prolactinomas, or prolactin-secreting adenomas, constitute the most common type of hyperfunctioning pituitary adenoma.
|
24135847 |
2014 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Regarding tumor type, adrenocorticotropic hormone (ACTH), prolactin (PRL), growth hormone (GH), non-functioning and multiple-secreting adenomas accounted for 35.7%, 25.7%, 12.2%, 25.7%, and 0.7% of the tumors, respectively.
|
31376772 |
2019 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Five ACTH producing adenomas, 11 GH producing adenomas, one PRL producing adenoma and five non-functioning adenomas were obtained at surgery.
|
7923822 |
1994 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Comparing ISH with immunohistology (IH) we found a correlation between signals and hormone content in 100% of adenomas for GH, in 60% for Prolactin and in 10% for Gonadotropins.
|
1923947 |
1991 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.
|
30400048 |
2019 |